Fundraising Fox
Sermonix Pharmaceuticals
Columbus, US · Founded 2014 · Delaware corporation
Find your way into Sermonix Pharmaceuticals
Each arrow is one introduction. Sign up to fill in the first one.
Ask Isabel Zhang to introduce you to David Portman
You →Isabel · together at The Ohio State University Wexner Medical Center →David
Sign up to find every way you can get introduced to Sermonix Pharmaceuticals
- Your email: who you already know at Sermonix Pharmaceuticals, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Sermonix Pharmaceuticals team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Sermonix Pharmaceuticals is a privately held biotechnology company developing female-specific oncology products, with a lead investigational drug, lasofoxifene, being studied for breast and ovarian cancer. Its ELAINE study evaluates lasofoxifene versus fulvestrant in women with ER+/HER2- metastatic breast cancer carrying an ESR1 mutation.
Founders & leadership
Sermonix Pharmaceuticals was founded in 2014 by David Portman.
Funding
SEC filings, press & company announcements$42.8M disclosed across 3 of 4 rounds · 2015–2021
- Undisclosed amountSeedNov 2017Source ↗
▶$40.2MraisedNov 2021 · 9 investors · PharmaceuticalsRule 506(b)
- Anthony WildExecutive Officer, Director
- Miriam PortmanExecutive Officer, Promoter
- Elizabeth AttiasExecutive Officer
- Michael FriedmanDirector
- Simon JenkinsExecutive Officer
- Elizabeth GarnerDirector
- David PortmanExecutive Officer, Director, Promoter
- Richard De SchutterDirector
- Barry KommExecutive Officer
- Thomas PfistererDirector
- Paul PlourdeExecutive Officer
- Offering amount
- $40.2M
- Amount sold
- $40.2M
- Sales commissions
- $2.2M
- Placement agents
- LIFESCI CAPITAL
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.6MraisedJul 2016 · 2 investors · PharmaceuticalsRule 506(b)
- Miriam PortmanExecutive Officer, Director
- David PortmanExecutive Officer, Director
- Patrick WieselDirector
- Offering amount
- $2.5M
- Amount sold
- $1.6M
- Minimum investment
- $25K
- First sale
- Jul 2016
- Incorporated
- Limited Liability Company, Ohio, 2014
- Federal exemptions
- 06b
▶$1MraisedOct 2015 · 17 investors · PharmaceuticalsRule 506(b)
- Miriam PortmanExecutive Officer
- David PortmanExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $1M
- Minimum investment
- $50K
- First sale
- Sep 2015
- Incorporated
- Limited Liability Company, Ohio, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Sermonix Pharmaceuticals.
Frequently asked questions
- What does Sermonix Pharmaceuticals do?
- Sermonix Pharmaceuticals is a privately held biotechnology company developing female-specific oncology products, with a lead investigational drug, lasofoxifene, being studied for breast and ovarian cancer. Its ELAINE study evaluates lasofoxifene versus fulvestrant in women with ER+/HER2- metastatic breast cancer carrying an ESR1 mutation.
- Who founded Sermonix Pharmaceuticals?
- Sermonix Pharmaceuticals was founded by David Portman in 2014.
- How much funding has Sermonix Pharmaceuticals raised?
- Sermonix Pharmaceuticals has disclosed $42.8M raised across 3 of its 4 known rounds.
- Where is Sermonix Pharmaceuticals headquartered?
- Sermonix Pharmaceuticals is headquartered in Columbus, US.